Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · IEX Real-Time Price · USD
7.44
+0.06 (0.81%)
At close: Jul 26, 2024, 4:00 PM
7.45
+0.01 (0.13%)
After-hours: Jul 26, 2024, 4:55 PM EDT
Amneal Pharmaceuticals Revenue
Amneal Pharmaceuticals had revenue of $659.19M in the quarter ending March 31, 2024, with 18.23% growth. This brings the company's revenue in the last twelve months to $2.50B, up 9.82% year-over-year. In the year 2023, Amneal Pharmaceuticals had annual revenue of $2.39B with 8.20% growth.
Revenue (ttm)
$2.50B
Revenue Growth
+9.82%
P/S Ratio
0.93
Revenue / Employee
$324,059
Employees
7,700
Market Cap
2.30B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.39B | 181.30M | 8.20% |
Dec 31, 2022 | 2.21B | 118.64M | 5.67% |
Dec 31, 2021 | 2.09B | 101.15M | 5.08% |
Dec 31, 2020 | 1.99B | 366.15M | 22.51% |
Dec 31, 2019 | 1.63B | -36.62M | -2.20% |
Dec 31, 2018 | 1.66B | 629.34M | 60.88% |
Dec 31, 2017 | 1.03B | 15.43M | 1.52% |
Dec 31, 2016 | 1.02B | 151.95M | 17.54% |
Dec 31, 2015 | 866.28M | 80.66M | 10.27% |
Dec 31, 2014 | 785.62M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Patterson Companies | 6.57B |
Ardent Health Partners | 5.53B |
AMN Healthcare Services | 3.48B |
Fortrea Holdings | 3.01B |
Privia Health Group | 1.69B |
Addus HomeCare | 1.09B |
10x Genomics | 625.45M |
Janux Therapeutics | 7.29M |
AMRX News
- 15 days ago - Amneal to Report Second Quarter 2024 Results on August 9, 2024 - Business Wire
- 17 days ago - Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant - Business Wire
- 25 days ago - Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar - Business Wire
- 25 days ago - Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab) - Business Wire
- 4 weeks ago - Amneal Releases 2023 Environmental, Social and Governance Report - Business Wire
- 7 weeks ago - Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies - Business Wire
- 2 months ago - Amneal to Participate at Upcoming Investor Conference - Business Wire
- 2 months ago - Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California - Business Wire